Image analysis systems for the detection of disseminated breast cancer cells on bone-marrow cytospins

Journal of Clinical Laboratory Analysis

Volumn 19, Issue 3, 2005, Pages 115-119

  Becker, Sven ^a   Becker Pergola, Graziella ^a   Fehm, Tanja ^a   Emig, Robert ^a   Wallwiener, Diethelm ^a   Solomayer, Erich Franz ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Immunocytology; Immunohistochemistry; Micrometastases; Minimal residual disease; Occult tumor cells

Indexed keywords

CYTOKERATIN; CYTOSPIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EVALUATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; LABORATORY AUTOMATION; MAJOR CLINICAL STUDY; REPRODUCIBILITY; SCREENING TEST;

BIOPSY, NEEDLE; BONE MARROW; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED;

ACIS;

EID: 19744380660     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcla.20064     Document Type: Article

References (16)

1. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: 31a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534-1539.
2. Braun S, Rosenberg R, Thorban S, Harbeck N. Implications of occult metastatic cells for systemic cancer treatment in patients with breast of gastrointestinal cancer. Semin Surg Oncol 2001;20:334-346.
3. Waldmann V, Deichmann M, Jackel A. Disseminated melanoma cells in blood and bone marrow. Significance and detection by potential tumor markers. Hautarzt 2001;52:298-303.
4. Heiss MM, Simon EH, Beyer BC, et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002;20:2005-2016.
5. Mansi JL, Easton D, Berger U, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991;27:1552-1555.
6. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-533.
7. Cote RJ, Beattie EJ, Chaiwun B, et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995;222:415-423.
8. Solomayer EF, Diel IJ, Salanti G, et al. Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 2001;7: 4102-4108.
9. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998;16:557-566.
10. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999;91:1113-1124.
11. Diel IJ, Cote RJ. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat Rev 2000;26:53-65.
12. Bauer KD, de la Torre-Bueno J, Diel IJ, et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000;6:3552-3559.
13. Borgen E, Naume B, Nesland JM, et al. The European ISHAGE Working Group for Standardization of Tumor Cell Detection: standardization of the immunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999;5:377-388.
14. Kraeft SK, Sutherland R, Gravelin L, et al. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin Cancer Res 2000;6:434-442.
15. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary breast cancer patients with micrometastases: a long-term follow-up study. Lancet 1999;354:197-202.
16. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery-prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88: 1652-1658.